1-7 of 7
Richard Labotka, MD MS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies

Meletios A. Dimopoulos, Jacob Laubach, MD, Maria Asuncion Echeveste Gutierrez, Norbert Grząśko, Craig C Hofmeister, MDMPH, Jesus F. San Miguel, MD, Shaji K Kumar, MD, Vickie Lu, PhD, Zhaoyang Teng, PhD, Guohui Liu, PhD, Catriona Byrne, RN, Deborah Berg, RN, MSN, Richard Labotka, MD MS, Helgi van de Velde, MD PhD, Paul G Richardson, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 902.
https://doi.org/10.1182/blood.V130.Suppl_1.902.902
Published: 2017
Journal Articles

Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Shaji Kumar, MD, Norbert Grzasko, MD PhD, Sosana Delimpasi, MD, Wieslaw W Jędrzejczak, MD, Sebastian Grosicki, MD PhD, Marie-Christine Kyrtsonis, MD PhD, Andrew Spencer, Neeraj Gupta, PhD, Zhaoyang Teng, PhD, Catriona Byrne, RN, Richard Labotka, MD MS, Meletios A Dimopoulos
Journal: Blood
Blood (2016) 128 (22): 3327.
https://doi.org/10.1182/blood.V128.22.3327.3327
Published: 2016
Journal Articles

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Meletios A. Dimopoulos, Sebastian Grosicki, MD PhD, Wieslaw W Jedrzejczak, MDPhD, Hareth Nahi, Astrid Gruber, MD PhD, Markus Hansson, Catriona Byrne, RN, Richard Labotka, MD MS, Ai-Min Hui, MD PhD, Zhaoyang Teng, PhD, Norbert Grzasko, MD PhD
Journal: Blood
Blood (2015) 126 (23): 26.
https://doi.org/10.1182/blood.V126.23.26.26
Published: 2015
Journal Articles

Treatment Patterns and Outcomes Among Patients Who Initiate Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care

Dorothy Romanus, RPh, MSc, PhD, Mehul Jhaveri, PharmD, PhD, Richard Labotka, MD MS, Henry Henk, PhD, Brian Seal, RPh, MBA, PhD
Journal: Blood
Blood (2015) 126 (23): 4515.
https://doi.org/10.1182/blood.V126.23.4515.4515
Published: 2015
Journal Articles

Healthcare Resource Use and Costs Among Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Dorothy Romanus, RPh, MSc, PhD, Brian Seal, RPh, MBA, PhD, Mehul Jhaveri, PharmD, PhD, Richard Labotka, MD MS, Henry Henk, PhD
Journal: Blood
Blood (2015) 126 (23): 4516.
https://doi.org/10.1182/blood.V126.23.4516.4516
Published: 2015
Journal Articles

Predictors of Second-Line Treatment Choice with Triplet Therapy in Routine Care Among Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Dorothy Romanus, RPh, MSc, PhD, Mehul Jhaveri, PharmD, PhD, Richard Labotka, MD MS, Henry Henk, PhD, Brian Seal, RPh, MBA, PhD
Journal: Blood
Blood (2015) 126 (23): 3309.
https://doi.org/10.1182/blood.V126.23.3309.3309
Published: 2015
Journal Articles

A Phase 1 Study to Assess Pharmacokinetics (PK) and Safety of Ixazomib, an Oral Proteasome Inhibitor, in Patients with Moderate or Severe Hepatic Impairment

Neeraj Gupta, PhD, Michael J Hanley, PhD, Karthik Venkatakrishnan, PhD, Raymond Perez, MD, Robin E Norris, MD, John Nemunaitis, MD, Huyuan Yang, PhD, Gerald Falchook, MD, Richard Labotka, MD MS, Siqing Fu, MD PhD
Journal: Blood
Blood (2015) 126 (23): 3032.
https://doi.org/10.1182/blood.V126.23.3032.3032
Published: 2015